Potent Cross-Group Neutralization of Primary Human Immunodeficiency Virus Isolates with Monoclonal Antibodies - Implications for Acquired Immunodeficiency Syndrome Vaccine

Journal of Infectious Diseases

Volumn 189, Issue 1, 2004, Pages 71-74

  Ferrantelli, Flavia ^a,b   Kitabwalla, Moiz ^a,b   Rasmussen, Robert A ^a,b   Cao, Chuanhai ^d   Chou, Ting Chao ^e   Katinger, Hermann ^g   Stiegler, Gabriela ^g   Cavacini, Lisa A ^b,c   Bai, Yun ^d   Cotropia, Joseph ^f   Ugen, Kenneth E ^d   Ruprecht, Ruth M ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f BioClonetics Inc   (United States)

^g UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 2G12; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY CL3; MONOCLONAL ANTIBODY F105; MONOCLONAL ANTIBODY F424; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CLADISTICS; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PASSIVE IMMUNIZATION; PHYLOGENY; PRIORITY JOURNAL; VIRUS CLASSIFICATION; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

AIDS VACCINES; ANTIBODIES, MONOCLONAL; CROSS REACTIONS; DRUG DESIGN; HIV ANTIBODIES; HIV-1; HUMANS; NEUTRALIZATION TESTS; VARIATION (GENETICS);

EID: 9144242884     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/380102     Document Type: Article

References (25)

1. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol 1991; 146:4325-32.
2. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994;68:4821-8.
3. Cotropia J, Ugen KE, Kliks S, et al. A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:221-32.
4. Viveros M, Dickey C, Cotropia JP, et al. Characterization of a novel human immunodeficiency virus type 1 neutralizable epitope within the immunodoniinant region of gp41. Virology 2000;270:135-45.
5. Zwick MB, Labrijn AF, Wang M, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001;75:10892-905.
6. Stiegler G, Kunert R, Purtscher M, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001;17:1757-65.
7. Muster T, Steindl F, Purtscher M, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67:6642-7.
8. Parker CE, Deterding LJ, Hager-Braun C, et al. Fine definition of the epitope on the gp41 glycoprotein of human immunodeficiency virus type 1 for the neutralizing monoclonal antibody 2F5. J Virol 2001;75:10906-11.
9. Hofmann-Lehmann R, Vlasak J, Rasmussen RA, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001;75:7470-80.
10. Gurtler LG, Hauser PH, Eberle J, et al. A new subtype of human immunodeficiency virus type 1 (MVP-5180) from Cameroon. J Virol 1994; 68:1581-5.
11. Loussert-Ajaka I, Chaix ML, Korber B, et al. Variability of human immunodeficiency virus type 1 group O strains isolated from Cameroonian patients living in France. J Virol 1995;69:5640-9.
12. Descamps D, Collin G, Letourneur F, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol 1997;71:8893-8.
13. Kitabwalla M, Ferrantelli F, Wang T, et al. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. AIDS Res Hum Retroviruses 2003;19:125-31.
14. Crawford JM, Earl PL, Moss B, et al. Characterization of primary isolate-like variants of simian-human immunodeficiency virus. J Virol 1999;73:10199-207.
15. Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003;422:307-12.
16. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHTV89.6P infection or disease in neonatal macaques. AIDS 2003;17:301-9.
17. Xu W, Smith-Franklin BA, Li PL, et al. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. J Hum Virol 2001;4:55-61.
18. Verrier F, Nadas A, Gorny MK, Zolla-Pazner S. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol 2001;75:9177-86.
19. Trkola A, Pomales AB, Yuan H, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995;69:6609-17.
20. Goudsmit J, Meloen RH, Brasseur R. Map of sequential B cell epitopes of the HIV-1 transmembrane protein using human antibodies as probe. Intervirology 1990;31:327-38.
21. Chan DC, Kim PS. HIV entry and its inhibition. Cell 1998;93:681-4.
22. Veazey RS, Shattock RJ, Pope M, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003;9:343-6.
23. Ferrantelli F, Ruprecht RM. Neutralizing monoclonal antibodies against HIV - back in the major leagues? Curr Opin Immunol 2002;14:495-502.
24. Barouch DH, Kunstman J, Kuroda MJ, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002;415:335-9.
25. Altfeld M, Allen TM, Yu XG, et al. HIV-1 superinfection despite broad CD8+ T-cell responses containing replication of the primary virus. Nature 2002;420:434-9.